FimmCyte and Richter Collaborate on Endometriosis Breakthrough – Startupticker.ch
Startupticker.ch shared a post on LinkedIn։
“FimmCyte, a femtech company developing new treatments for endometriosis, has entered into a research collaboration and option-to-license agreement with Richter, a leading Hungarian pharmaceutical company, to advance research on its lead clinical candidate, FMC2. The parties have fully negotiated a definitive, exclusive and worldwide license agreement for the future development and commercialization of the antibody. FimmCyte will be eligible to receive development and commercial milestone payments, together with tiered royalties on net sales, as provided under the pre-agreed license agreement.
More about FimmCyte, its clinical candidate and the collaboration in our article․”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Jul 15, 2026, 15:57Early Bird Registration Opens for RCOG Female Reproductive Physiology Course – RCOG
-
Jul 15, 2026, 15:53ACOG Joins Coalition to Advance National Women’s Health Strategy – ACOG
-
Jul 15, 2026, 15:44From the Shadow of Pregnancy Loss to a New Pregnancy – RBMO
-
Jul 15, 2026, 15:27Supporting the Launch of the National Strategy to Close the Women’s Health Gap – ASRM
-
Jul 15, 2026, 15:21Sergio Haimovich: AI Is Already Reshaping Scientific Publishing and Disclosure Is Lagging Behind
-
Jul 15, 2026, 15:12The Egg’s Engine Is Fed Plenty of Fuel, It Just Can’t Burn It – Fertility Plus
-
Jul 15, 2026, 15:07Join the Ultrasound in Obstetrics and Gynecology Team as the UOG Social Media Editor – ISUOG
-
Jul 15, 2026, 14:56Can Ultrasound Reliably Detect Residual Cervical Cancer After Conization? – IJGC
-
Jul 15, 2026, 14:27Marco Zaccaria: A Great Webinar, Hosted By BSGE and BMUS